Welcome to Lanthio Pharma
Lanthio Pharma is a Dutch biopharmaceutical company committed to developing and commercializing therapeutic peptides against difficult to target receptors (e.g. GPCRs). With its proprietary LanthioPep technology, the company is generating peptide drugs that are markedly enhanced for stability and selectivity.
Utilizing our technology we are building a growing pipeline of stabilized, receptor specific lanthipeptides with the potential for treatment of fibrosis, heart failure and multiple sclerosis.
Lanthio’s lead product, LP2, is a selective AT2 receptor agonist, in development for Diabetic Nephropathy, with possible further applications in IPF and other fibrotic diseases.
LP2 is currently in preclinical development, with the expectation that First in Man studies will start in 2015.